MetaCap

Eloxx Pharmaceuticals Inc. (ELOX)

NASDAQ: ELOXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

10.69-0.19 (-1.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ELOX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$43.69M
52-week range
8.20 – 23.40
Day range
10.03 – 10.94
Volume / Avg
14.98K / 28.48K
Beta
—

52-week range

$8.20$23.40

ELOX stock today

On Nov 20, ELOX ended the session at $10.69, shedding $0.19 (1.75%), versus the S&P 500's 3.70% decline. At this level, ELOX sits near the bottom of its 52-week range of $8.20 to $23.40: 54.3% below the high, set on Aug 21, 2026 and 30.4% above the low. Eloxx Pharmaceuticals trades at 5.6x its trailing twelve-month earnings per share of $1.90.

Summary generated from market data by MetaCap's automated system. Methodology

About Eloxx Pharmaceuticals

Company profile

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Sumit Aggarwal M.B.A.
Headquarters
Arlington, MA
Employees
10

Financial highlights

Full financials

In fiscal 2025, Eloxx Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2013. Eloxx Pharmaceuticals reported a net loss of $6.0 million, compared with a loss of $3.1 million a year earlier. Diluted earnings per share came in at -$0.49.

Eloxx Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$6.36M$0——
Growth-100.00%————
Net income$-6.00M$-3.14M$-17.05M$-36.06M$-66.73M
EPS (diluted)$-0.49$-0.84$-6.63$-16.65$-38.15

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$38.25+257.81%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $32.00High $43.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.49 vs —

ELOX news

All ELOX news

Eloxx Pharmaceuticals peers

Health Care sector
ELOX peer companies
CompanyPrice% ChgMarket capCompare
GRMLGreenland Mines Ltd.2.99+2.75%$44.31Mvs ELOX
INKTMiNK Therapeutics Inc.8.02-6.85%$41.17Mvs ELOX
ELUTElutia Inc. Class A0.9001+11.12%$39.96Mvs ELOX
IMAImageneBio Inc.3.920.00%$48.83Mvs ELOX
TILInstil Bio Inc.5.23-5.77%$35.47Mvs ELOX
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs ELOX
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs ELOX
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs ELOX

Indexes, lists and sector

Eloxx Pharmaceuticals stock FAQ

What is Eloxx Pharmaceuticals's stock price today?

ELOX last traded at $10.69 as of Nov 20, 4:00 PM EST, down 1.75% on the day. Prices are delayed at least 15 minutes.

What is ELOX's P/E ratio?

ELOX trades at a trailing P/E ratio of 5.63.

Who is Eloxx Pharmaceuticals's CEO?

Mr. Sumit Aggarwal M.B.A. is the chief executive officer of Eloxx Pharmaceuticals Inc., which has about 10 employees.

What is the ELOX 52-week high?

The 52-week high for ELOX is $23.40 and the 52-week low is $8.20. The stock is currently 54.3% below its high.

Compare ELOX